Europe - EMA - European Medicines Agency
Incresync (Active substance: alogliptin / pioglitazone) - Centralised - Renewal - Commission Decision (2018)3347 of Mon, 28 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2178/R/23
Europe -DG Health and Food Safety
Registration is free.
myHealthbox can improve the online visibility of your products by as much as 20%.
Contact us to find out more.
myHealthbox™ is a leading provider of health information services to consumers and healthcare professionals.